Bevacizumab, which comes in injection form, is marketed under the trade name Bevatas. Vascular endothelial growth factor (VEGF), a protein involved in angiogenesis (the creation of new blood vessels), is the target of the monoclonal antibody bevacizumab. Bevacizumab aids in preventing the growth and spread of blood vessels that feed tumours by inhibiting VEGF. It is mainly employed in the management of different forms of cancer.
1. Bevacizumab is used to treat advanced or metastatic colorectal cancer in conjunction with chemotherapy.
2. Non-Small Cell Lung Cancer (NSCLC): In some situations of advanced NSCLC, it is used with chemotherapy.
3. Glioblastoma: The brain tumour bevacizumab is used to treat recurrent glioblastoma.
4. Advanced Renal Cell Carcinoma: It is used in conjunction with interferon alfa to treat this condition.
5. Ovarian Cancer: In some situations of advanced ovarian cancer, bevacizumab is used with chemotherapy.
6. In some situations of advanced cervical cancer, it is used in conjunction with chemotherapy.
Usually, bevacizumab is given as an intravenous (IV) infusion, which means that it enters the bloodstream through a vein.
Bevacizumab may have adverse effects, which might vary depending on the particular medical condition being treated as well as other personal characteristics, like all drugs do. High blood pressure, exhaustion, problems with bleeding or clotting, proteinuria (extra protein in the urine), and gastrointestinal perforations are examples of common side effects. Bevacizumab patients must be regularly watched by their medical professionals in order to manage and treat any potential adverse effects.
Bevacizumab should only be administered by a trained healthcare expert after carefully considering the patient's unique medical history and current state, as with any cancer treatment. It is crucial to speak with your doctor if you have questions about Bevatas (bevacizumab), have been prescribed it, or both.